lnc-IL7R Expression Reflects Physiological Pulmonary Function and Its Aberration Is a Putative Indicator of COPD

Area of Science:

• Pulmonary Medicine
• Molecular Biology
• Genetics

Background:

• Chronic obstructive pulmonary disease (COPD) presents a significant global health challenge due to limited curative treatments and a lack of specific molecular biomarkers.
• Inflammation, lung injury, and aging are implicated in COPD development and progression.
• The role of the long noncoding RNA lnc-IL7R in pulmonary health and COPD pathogenesis is largely unexplored.

Purpose of the Study:

• To investigate the expression and clinical significance of lnc-IL7R in patients with COPD.
• To determine if lnc-IL7R can serve as a diagnostic or prognostic biomarker for COPD.
• To explore the therapeutic potential of lnc-IL7R in COPD.

Main Methods:

• Quantitative analysis of lnc-IL7R expression in a cohort of 125 COPD patients.
• Correlation analysis between lnc-IL7R levels and pulmonary function tests (e.g., FEV1, FVC, GOLD stage).
• Bioinformatic analysis to assess the dose-response relationship between lnc-IL7R expression and COPD probability.

Main Results:

• lnc-IL7R levels were significantly correlated with physiological pulmonary function and stratified COPD patients (AUC = 0.86).
• lnc-IL7R correctly identified COPD patients (sensitivity=0.83, specificity=0.83) and discriminated non-emphysematous phenotypes (sensitivity=0.48, specificity=0.89).
• Reduced lnc-IL7R expression correlated with disease severity (GOLD stage, %LAA-950insp, total LAA) and impaired lung function (FEV1%, FVC%, FEV1/FVC).

Conclusions:

• Decreased lnc-IL7R expression is associated with airway inflammation and impaired pulmonary function in COPD.
• lnc-IL7R serves as a potential pathognomonic biomarker for COPD and predicts an aggravated phenotype.
• lnc-IL7R represents a novel therapeutic target for managing COPD.